Dolutegravir use in combination with rifampicin-based tuberculosis therapy: 3 years of real-world experience in a large UK teaching hospital

Muge Cevik; Hugh McGann

doi:10.1136/sextrans-2018-053698

Dolutegravir use in combination with rifampicin-based tuberculosis therapy: 3 years of real-world experience in a large UK teaching hospital

Muge Cevik^*
, Hugh McGann

^*Corresponding author for this work

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English
Article number	420
Number of pages	1
Journal	Sexually Transmitted Infections
Volume	94
Issue number	6
Early online date	20 Aug 2018
DOIs	https://doi.org/10.1136/sextrans-2018-053698
Publication status	Published - Sept 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antiretroviral therapy
Audit
HIV
Infectious diseases
Tuberculosis

Access to Document

10.1136/sextrans-2018-053698

Handle.net

Persistent link

Cite this

@article{a877e3b145974730aa42b318c75c8176,

title = "Dolutegravir use in combination with rifampicin-based tuberculosis therapy: 3 years of real-world experience in a large UK teaching hospital",

keywords = "Antiretroviral therapy, Audit, HIV, Infectious diseases, Tuberculosis",

author = "Muge Cevik and Hugh McGann",

year = "2018",

month = sep,

doi = "10.1136/sextrans-2018-053698",

language = "English",

volume = "94",

journal = "Sexually Transmitted Infections",

issn = "1368-4973",

publisher = "BMJ Publishing Group",

number = "6",

}

TY - JOUR

T1 - Dolutegravir use in combination with rifampicin-based tuberculosis therapy

T2 - 3 years of real-world experience in a large UK teaching hospital

AU - Cevik, Muge

AU - McGann, Hugh

PY - 2018/9

Y1 - 2018/9

KW - Antiretroviral therapy

KW - Audit

KW - HIV

KW - Infectious diseases

KW - Tuberculosis

U2 - 10.1136/sextrans-2018-053698

DO - 10.1136/sextrans-2018-053698

M3 - Letter

C2 - 30030303

AN - SCOPUS:85050620239

SN - 1368-4973

VL - 94

JO - Sexually Transmitted Infections

JF - Sexually Transmitted Infections

IS - 6

M1 - 420

ER -